Journal of Antimicrobial Chemotherapy (2002) 49, 507-513
© 2002 The British Society for Antimicrobial Chemotherapy
Experimental study of the efficacy of vancomycin, rifampicin and dexamethasone in the therapy of pneumococcal meningitis
a Laboratory of Experimental Infection, Infectious Diseases Service and b Microbiology Service, Ciutat Sanitària i Universitaria de Bellvitge, Barcelona, Spain
The object of the study was to assess the efficacy of rifampicin and the combination of rifampicin plus vancomycin in a rabbit model of experimental penicillin-resistant pneumococcal meningitis. We also studied the effect of concomitant dexamethasone on the CSF antibiotic levels and inflammatory parameters. The rabbit model of pneumococcal meningitis was used. Groups of eight rabbits were inoculated with 106 cfu/mL of a cephalosporin-resistant pneumococcal strain (MIC of cefotaxime/ceftriaxone 2 mg/L). Eighteen hours later they were treated with rifampicin 15 mg/kg/day, vancomycin 30 mg/kg/day or both ± dexamethasone (0.25 mg/kg/day) for 48 h. Serial CSF samples were withdrawn to carry out bacterial counts, antibiotic concentration and inflammatory parameters. Rifampicin and vancomycin promoted a reduction of >3 log cfu/mL at 6 and 24 h, and cfu were below the level of detection at 48 h. Combination therapy with vancomycin plus rifampicin was not synergic but it had similar efficacy to either antibiotic alone and it was able to reduce bacterial concentration below the level of detection at 48 h. Concomitant use of dexamethasone decreased vancomycin levels when it was used alone (P< 0.05), but not when it was used in combination with rifampicin. Rifampicin alone at 15 mg/kg/day produced a rapid bactericidal effect in this model of penicillin-resistant pneumococcal meningitis. The combination of vancomycin and rifampicin, although not synergic, proved to be equally effective. Using this combination in the clinical setting may allow rifampicin administration without emergence of resistance, and possibly concomitant dexamethasone administration without significant interference with CSF vancomycin levels.
* Correspondence address. Infectious Diseases Service, Hospital de Bellvitge, C/Feixa Llarga s/n, 08907 L'Hospitalet, Barcelona, Spain. Tel: +34-93-3357011 ext. 2487; Fax: +34-93-2607637; E-mail: ccabellos{at}csub.scs.es
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  U. Egermann, Z. Stanga, A. Ramin, F. Acosta, A. Stucki, P. Gerber, M. Cottagnoud, and P. Cottagnoud Combination of Daptomycin plus Ceftriaxone Is More Active than Vancomycin plus Ceftriaxone in Experimental Meningitis after Addition of Dexamethasone Antimicrob. Agents Chemother., July 1, 2009; 53(7): 3030 - 3033. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Stucki, P. Gerber, F. Acosta, M. Cottagnoud, P. Cottagnoud, L. Jiang, P. Nguyen, D. Wachtel, G. Wang, and L. T. Phan Effects of EDP-420 on penicillin-resistant and quinolone- and penicillin-resistant pneumococci in the rabbit meningitis model J. Antimicrob. Chemother., March 1, 2008; 61(3): 665 - 669. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Ribes, F. Taberner, A. Domenech, C. Cabellos, F. Tubau, J. Linares, P. F. Viladrich, and F. Gudiol Evaluation of fosfomycin alone and in combination with ceftriaxone or vancomycin in an experimental model of meningitis caused by two strains of cephalosporin-resistant Streptococcus pneumoniae J. Antimicrob. Chemother., May 1, 2006; 57(5): 931 - 936. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Ferrandiz, C. Ardanuy, J. Linares, J. M. Garcia-Arenzana, E. Cercenado, A. Fleites, A. G. de la Campa, and the Spanish Pneumococcal Infection Study Network New Mutations and Horizontal Transfer of rpoB among Rifampin-Resistant Streptococcus pneumoniae from Four Spanish Hospitals Antimicrob. Agents Chemother., June 1, 2005; 49(6): 2237 - 2245. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. Lewin III, M. Lapointe, and W. C. Ziai Central Nervous System Infections in the Critically Ill Journal of Pharmacy Practice, February 1, 2005; 18(1): 25 - 41. [Abstract] [PDF]
|
|
|
|
|
|
A. Fernandez, C. Cabellos, F. Tubau, J. M. Maiques, A. Domenech, S. Ribes, J. Linares, P. F. Viladrich, and F. Gudiol Experimental study of teicoplanin, alone and in combination, in the therapy of cephalosporin-resistant pneumococcal meningitis J. Antimicrob. Chemother., January 1, 2005; 55(1): 78 - 83. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Cabellos, A. Fernandez, J. M. Maiques, F. Tubau, C. Ardanuy, P. F. Viladrich, J. Linares, and F. Gudiol Experimental Study of LY333328 (Oritavancin), Alone and in Combination, in Therapy of Cephalosporin-Resistant Pneumococcal Meningitis Antimicrob. Agents Chemother., June 1, 2003; 47(6): 1907 - 1911. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. D Shafran Dexamethasone improved disability in acute bacterial meningitis Evid. Based Med., May 1, 2003; 8(3): 86 - 86. [Full Text] [PDF]
|
|